Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.02
- Piotroski Score 7.00
- Grade Hold
- Symbol (GRFS)
- Company Grifols, S.A.
- Price $8.60
- Changes Percentage (1.66%)
- Change $0.14
- Day Low $8.37
- Day High $8.61
- Year High $12.15
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
- Last Earnings 05/26/2021
- Ex-Dividend for 5/16 Dividend 06/03/2021
- Dividend Payable 06/14/2021
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.10
- Trailing P/E Ratio 72.4
- Forward P/E Ratio 72.4
- P/E Growth 72.4
- Net Income $59.32 M
Income Statement
Quarterly
Annual
Latest News of GRFS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Grifols, S.A. (GRFS) Stock Price, News, Quote & History - Yahoo Finance
Grifols, S.A. is a global plasma therapeutic company based in Spain. It provides a range of products for various medical conditions, including immunodeficiencies, genetic diseases, and hemophilia. The...
By Yahoo! Finance | 4 months ago
